Buyback Alert! This Bajaj Group Stock will buy shares at 19% premium to CMP — Check record date

Tata Motors to hike commercial vehicle prices by up to 2.5% from July 1

Stock Market Closing Bell: Sensex gains 255 points, Nifty ends above 24,150; PSU banks, healthcare stocks lead rally; IT drags

IndiGo launches ‘Cabs with IndiGo’ airport transfer service across India

India-UK FTA: Centre likely to issue notifications, announce customs changes by July 15

EPF Interest 2026: Government approves 8.25% interest rate for employee provident fund accounts

US and Iran sign peace deal; 60-day negotiations to continue for a permanent agreement

Turtlemint Fintech IPO Opens June 19: 6 key details investors should know before applying

52-Week High Alert: Nykaa jumps over 7% after unveiling FY30 plan to build $5 billion-plus business

Gold price crashes Rs 2,300 on MCX, Silver slides nearly Rs 7,000 — Why are precious metals falling?

Zydus Lifesciences reported a steady performance for the quarter and financial year ended FY26.&nbsp;The company also announced a share buyback and a final dividend for shareholders.

Zydus Lifesciences Q4 Results: Pharma giant declares 100% dividend and Rs 1,100 crore buyback plan — Check record dates

Zydus Lifesciences Q4 stuns with margin guidance, but brokerages trim targets — stock ends at Rs&nbsp;890. Should you follow Jefferies’ bullish call?

Jefferies says 'Buy' this strong pharma stock even after cutting target — Here’s how much you could earn from Zydus Lifesciences

Zydus Lifesciences shares rose 3% after receiving USFDA approval for Apalutamide Tablets, 60 mg.

Zydus Lifesciences jumps 8% as USFDA approves Apalutamide tablets

Stock Market: The domestic stock market had a weak start on Friday (July 5). There is selling pressure in banking shares. Amid the market decline, brokerage firm Motilal Oswal has made pharma sector giant Zydus Lifesciences a technical pick. Brokerage has advised buying in Zydus lifescience for 2-3 days.

Stock Market: Tremendous enthusiasm shown in this Pharma Stock, buying advice for 2-3 days

The approval by the US Food and Drug Administration (USFDA) is for Theophylline extended-release tablets of strengths 300 mg and 450 mg, Zydus Lifesciences said in a regulatory filing.

Zydus Lifesciences gets USFDA nod for asthma treatment drug

Zydus Lifesciences blasts through the roof, hitting a 52-week high after the US FDA greenlights a Phase II trial for its Parkinson's disease drug ZYIL1! This potential blockbuster medication targets a $2 billion market, setting Zydus on fire.

Zydus Lifesciences Hits Record High! US FDA Nod Boosts Stock 4.61% | Stock Market News